Telehealth Booms as Demand for GLP-1s Surges and Questions Mount About Safety, Oversight By Lauren Sausser and Maia Rosenfeld June 1, 2026

https://kffhealthnews.org/health-industry/glp1-weight-loss-drugs-telehealth-oversight-regulation-compounded-semaglutide/?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz-8QxJF6hJ_2t1zhlsL4ImM8r0Z0xYmU9eEiy7u-Klhpv2YUdPV0lnB9YHBAGaXxM9IyzV7a3QyY-1DxmgraRTmyqYBQ3Q&_hsmi=421585297&utm_content=421585297&utm_source=hs_email KFF Health News: Telehealth Booms As Demand For GLP-1s Surges And Questions Mount About Safety, Oversight Within 24 hours of injecting the first dose of a weight loss medication she received following a visit with a telehealth doctor, Karleigh McClain was admitted to the hospital, she said. The 31-year-old compliance consultant from Hendersonville, Tennessee, said she couldn’t stop vomiting. “Sunday morning, it all hits,” McClain recalled, as she described what happened that weekend in January. “I can’t keep anything down.” (Sausser and Rosenfeld, 6/1)